Letters to the Editor
Treatment of Aggression in Patients with Mental Retardation
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2007 Mar 1;75(5):622-624.
to the editor: The article, “Medical Care of Adults with Mental Retardation,” in American Family Physician, provides a brief introduction to behavioral and psychiatric treatment of patients with mental retardation.1 Psychopharmacologic management in this area is fraught with ethical concerns, diagnostic difficulties, and a tendency toward overmedicating. Physicians often prescribe antipsychotics to control aggressive behavior while missing an underlying mood or anxiety disorder. In many cases, antidepressants or beta blockers may be used to avoid the adverse effects of antipsychotics.
Aggressive behavior is the most common reason for psychiatric referral in persons with mental retardation. Patients who are mentally retarded should undergo a thorough diagnostic work-up to rule out specific medical or psychiatric causes of aggression. If no specific etiology is found, behavior therapy should be the initial approach. Most patients, however, are treated empirically with antipsychotic medications.2 Several studies suggest that patients who are mentally retarded are overmedicated with antipsychotics, resulting in sedation, social withdrawal, and loss of cognitive function.3 Newer antipsychotics have a lower incidence of akathisia and tardive dyskinesia but can predispose patients to obesity and metabolic syndrome. Retrospective data suggest that persons with mental retardation are at higher risk of sedation and weight gain than the general population.4 Therefore, it is desirable to restrict the use of antipsychotics when other classes of medications may have equal or better effectiveness at controlling aggression.
To guide appropriate prescribing, one author identified symptom clusters surrounding aggressive outbursts that may be classified into behavioral profiles responsive to certain medication classes.5 For example, patients with obsessive and ritualistic tendencies who become aggressive when interrupted may be considered to have an anxiety spectrum disorder and should respond to a selective serotonin reuptake inhibitor. Patients with severe affective lability or rage lasting for long periods may be considered manic or as having a mood spectrum disorder and should respond to lithium or an anticonvulsant. Patients with paranoia, delusions, or hallucinations may require the scheduled use of an antipsychotic.5
When there is no clear evidence of mania or an underlying psychotic process, an initial trial of a serotonergic antidepressant is indicated. Antidepressants can improve aggressive outbursts in patients with an underlying depressive or anxiety disorder, allowing for decreased reliance on antipsychotics.6 Occasional use of an antipsychotic may be necessary when aggressive outbursts become severe. Early psychiatric consultation is recommended when initial trials of antide-pressants have been ineffective, mania is suspected, or a psychotic process is present.
Author disclosure: Nothing to disclose.
The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department or the U.S. Army service at large.
1. Prater CD, Zylstra RG. Medical care of adults with mental retardation. Am Fam Physician. 2006;73:2175–83.
2. Matson JL, Bamburg JW, Mayville EA, Pinkston J, Bielecki J, Kuhn D, et al. Psychopharmacology and mental retardation: a 10 year review (1990–1999). Res Dev Disabil. 2000;21:263–96.
3. Ahmed Z, Fraser W, Kerr MP, Kiernan C, Emerson E, Robertson J, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry. 2000;176:42–6.
4. Simeon J, Milin R, Walker S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:267–75.
5. Ryan JM. Pharmacologic approach to aggression in neuropsychiatric disorders. Semin Clin Neuropsychiatry. 2000;5:238–49.
6. Janowsky DS, Shetty M, Barnhill J, Elamir B, Davis JM. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Int J Neuropsychopharmacol. 2005;8:37–48.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions